Literature DB >> 19355989

Computational studies on the histone deacetylases and the design of selective histone deacetylase inhibitors.

Difei Wang1.   

Abstract

The catalytic activity of the histone deacetylase (HDAC) enzymes is directly relevant to the pathogenesis of cancer as well as several other diseases. HDAC inhibitors have been shown to have the potential to treat several types of cancers. The role of computational study of the HDAC enzymes is reviewed, with particular emphasis on the important role of molecular modeling to the development of HDAC inhibitors with improved efficacy and selectivity. The use of two computational approaches--one structure-based, and the second ligand-based--toward inhibitors against the different HDAC sub-classes, are summarized.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19355989      PMCID: PMC2766262          DOI: 10.2174/156802609788085287

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  88 in total

1.  On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors.

Authors:  Di-Fei Wang; Olaf Wiest; Paul Helquist; Hsuan-Yin Lan-Hargest; Norbert L Wiech
Journal:  J Med Chem       Date:  2004-06-17       Impact factor: 7.446

2.  Quantitative structure-activity relationship study of histone deacetylase inhibitors.

Authors:  Aihua Xie; Chenzhong Liao; Zhibin Li; Zhiqiang Ning; Weiming Hu; Xianping Lu; Leming Shi; Jiaju Zhou
Journal:  Curr Med Chem Anticancer Agents       Date:  2004-05

3.  Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation.

Authors:  J E Brownell; J Zhou; T Ranalli; R Kobayashi; D G Edmondson; S Y Roth; C D Allis
Journal:  Cell       Date:  1996-03-22       Impact factor: 41.582

4.  HDAC6 expression is correlated with better survival in breast cancer.

Authors:  Zhenhuan Zhang; Hiroko Yamashita; Tatsuya Toyama; Hiroshi Sugiura; Yoko Omoto; Yoshiaki Ando; Keiko Mita; Maho Hamaguchi; Shin-Ichi Hayashi; Hirotaka Iwase
Journal:  Clin Cancer Res       Date:  2004-10-15       Impact factor: 12.531

5.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.

Authors:  John R Somoza; Robert J Skene; Bradley A Katz; Clifford Mol; Joseph D Ho; Andy J Jennings; Christine Luong; Andrew Arvai; Joseph J Buggy; Ellen Chi; Jie Tang; Bi-Ching Sang; Erik Verner; Robert Wynands; Ellen M Leahy; Douglas R Dougan; Gyorgy Snell; Marc Navre; Mark W Knuth; Ronald V Swanson; Duncan E McRee; Leslie W Tari
Journal:  Structure       Date:  2004-07       Impact factor: 5.006

6.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis.

Authors:  Ping Zhu; Elke Martin; Jörg Mengwasser; Peter Schlag; Klaus-Peter Janssen; Martin Göttlicher
Journal:  Cancer Cell       Date:  2004-05       Impact factor: 31.743

7.  Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.

Authors:  Alessandro Vannini; Cinzia Volpari; Gessica Filocamo; Elena Caroli Casavola; Mirko Brunetti; Debora Renzoni; Prasun Chakravarty; Chantal Paolini; Raffaele De Francesco; Paola Gallinari; Christian Steinkühler; Stefania Di Marco
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

8.  Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

Authors:  Ivan V Gregoretti; Yun-Mi Lee; Holly V Goodson
Journal:  J Mol Biol       Date:  2004-04-16       Impact factor: 5.469

Review 9.  The Sir2 family of protein deacetylases.

Authors:  Gil Blander; Leonard Guarente
Journal:  Annu Rev Biochem       Date:  2004       Impact factor: 23.643

10.  Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer.

Authors:  Kalipso Halkidou; Luke Gaughan; Susan Cook; Hing Y Leung; David E Neal; Craig N Robson
Journal:  Prostate       Date:  2004-05-01       Impact factor: 4.104

View more
  12 in total

1.  Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis.

Authors:  Qi Shi; Thomas M Kaiser; Zackery W Dentmon; Mariangela Ceruso; Daniela Vullo; Claudiu T Supuran; James P Snyder
Journal:  ACS Med Chem Lett       Date:  2015-04-03       Impact factor: 4.345

Review 2.  Metabolism as a key to histone deacetylase inhibition.

Authors:  Praveen Rajendran; David E Williams; Emily Ho; Roderick H Dashwood
Journal:  Crit Rev Biochem Mol Biol       Date:  2011-04-05       Impact factor: 8.250

3.  Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites.

Authors:  Paris R Watson; Timothy W Craven; Xinting Li; Stephen Rettie; Parisa Hosseinzadeh; Fátima Pardo-Avila; Asim K Bera; Vikram Khipple Mulligan; Peilong Lu; Alexander S Ford; Brian D Weitzner; Lance J Stewart; Adam P Moyer; Maddalena Di Piazza; Joshua G Whalen; Per Jr Greisen; David W Christianson; David Baker
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

4.  Targeting Several Biologically Reported Targets of Glioblastoma Multiforme by Assaying 2D and 3D Cultured Cells.

Authors:  Yudibeth Sixto-López; Emilie Marhuenda; Juan Benjamin García-Vazquez; Manuel Jonathan Fragoso-Vazquez; Martha Cecilia Rosales-Hernández; Oscar Zacarías-Lara; David Méndez-Luna; José Antonio Gómez-Vidal; David Cornu; Bakalara Norbert; José Correa-Basurto
Journal:  Cell Mol Neurobiol       Date:  2021-03-19       Impact factor: 5.046

5.  In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC).

Authors:  Usman S F Tambunan; N Bramantya; Arli A Parikesit
Journal:  BMC Bioinformatics       Date:  2011-11-30       Impact factor: 3.169

6.  Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer.

Authors:  Danqi Chen; Aijun Shen; Guanghua Fang; Hongchun Liu; Minmin Zhang; Shuai Tang; Bing Xiong; Lanping Ma; Meiyu Geng; Jingkang Shen
Journal:  Acta Pharm Sin B       Date:  2016-01-07       Impact factor: 11.413

7.  HDAC inhibitors in experimental liver and kidney fibrosis.

Authors:  Katrien Van Beneden; Inge Mannaerts; Marina Pauwels; Christiane Van den Branden; Leo A van Grunsven
Journal:  Fibrogenesis Tissue Repair       Date:  2013-01-02

8.  Molecular modeling study on tunnel behavior in different histone deacetylase isoforms.

Authors:  Sundarapandian Thangapandian; Shalini John; Yuno Lee; Venkatesh Arulalapperumal; Keun Woo Lee
Journal:  PLoS One       Date:  2012-11-29       Impact factor: 3.240

Review 9.  HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?

Authors:  Claudia Simões-Pires; Vincent Zwick; Alessandra Nurisso; Esther Schenker; Pierre-Alain Carrupt; Muriel Cuendet
Journal:  Mol Neurodegener       Date:  2013-01-29       Impact factor: 14.195

10.  HDAC6 Brain Mapping with [18F]Bavarostat Enabled by a Ru-Mediated Deoxyfluorination.

Authors:  Martin G Strebl; Arthur J Campbell; Wen-Ning Zhao; Frederick A Schroeder; Misha M Riley; Peter S Chindavong; Thomas M Morin; Stephen J Haggarty; Florence F Wagner; Tobias Ritter; Jacob M Hooker
Journal:  ACS Cent Sci       Date:  2017-09-06       Impact factor: 14.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.